Nikhil Bharti

Nikhil Bharti

Auto-generated profile, based on publicly available information

Nikhil Bharti

Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 May 2023 in Nature
Verified
Journal Article
Open access
PDF file
SASuki Albers
Suki Albers
EAElizabeth C. Allen
Elizabeth C. Allen
NBNikhil Bharti
Nikhil Bharti
MDMarcos Davyt
Marcos Davyt
DJDisha Joshi
Disha Joshi
ZIZoya Ignatova
Zoya Ignatova
Nonsense mutations are the underlying cause of approximately 11% of all inherited genetic diseases1. Nonsense mutations convert a sense codon that is decoded by tRNA into a premature termination codon (PTC), resulting in an abrupt termination of translation. One strategy to suppress nonsense mutations is to use natural tRNAs with altered anticodons to base-pair to the newly emerged PTC and promote translation2–7. However, tRNA-based gene therapy has not yielded an optimal combination of clinical efficacy and safety and there is presently no treatment for individuals with nonsense mutations. Here we introduce a strategy based on altering native tRNAs into efficient suppressor tRNAs (sup-tRNAs) by individually fine-tuning their sequence to the physico-chemical properties of the amino acid that they carry. Intravenous and intratracheal lipid nanoparticle (LNP) administration of sup-tRNA in mice restored the production of functional proteins with nonsense mutations. LNP–sup-tRNA formulations caused no discernible readthrough at endogenous native stop codons, as determined by ribosome profiling. At clinically important PTCs in the cystic fibrosis transmembrane conductance regulator gene (CFTR), the sup-tRNAs re-established expression and function in cell systems and patient-derived nasal epithelia and restored airway volume homeostasis. These results provide a framework for the development of tRNA-based therapies with a high molecular safety profile and high efficacy in targeted PTC suppression.

5 April 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
NBNikhil Bharti
Nikhil Bharti
LSLeonardo Santos
Leonardo Santos
MDMarcos Davyt
Marcos Davyt
SBStine Behrmann
Stine Behrmann
MEMarie Eichholtz
Marie Eichholtz
ZIZoya Ignatova
Zoya Ignatova
Nonsense mutations – the underlying cause of approximately 11% of all genetic diseases – prematurely terminate protein synthesis by mutating a sense codon to a premature stop or termination codon (PTC). An emerging therapeutic strategy to suppress nonsense defects is to engineer sense-codon decoding tRNAs to readthrough and restore translation at PTCs. However, the readthrough efficiency of the engineered suppressor tRNAs (sup-tRNAs) largely varies in a tissue- and sequence context-dependent manner and has not yet yielded optimal clinical efficacy for many nonsense mutations. Here, we systematically analyze the suppression efficacy at various pathogenic nonsense mutations. We discover that the translation velocity of the sequence upstream of PTCs modulates the sup-tRNA readthrough efficacy. The PTCs most refractory to suppression are embedded in a sequence context translated with an abrupt reversal of the translation speed leading to ribosomal collisions. Moreover, modeling translation velocity using Ribo-seq data can accurately predict the suppression efficacy at PTCs. These results reveal previously unknown molecular signatures contributing to genotype-phenotype relationships and treatment-response heterogeneity, and provide the framework for the development of personalized tRNA-based gene therapies.

9 January 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
UJUrmila Jagtap
Urmila Jagtap
SBSandeep Basu
Sandeep Basu
LLLavanya Lokhande
Lavanya Lokhande
NBNikhil Bharti
Nikhil Bharti
CSChetana Sachidanandan
Chetana Sachidanandan
The use of many essential drugs is restricted due to their deleterious effects on the liver. Molecules that can prevent or protect the liver from drug induced liver injury (DILI) would be valuable in such situations. We used hepatocyte-specific expression of bacterial nitroreductase in zebrafish to cause temporally controlled liver damage. This transgenic line was used to run a whole organism based chemical screen in zebrafish larvae. In this screen we identified BML-257, a potent small molecule AKT inhibitor, that protected the liver against metronidazole-induced liver injury. BML-257 also showed potent prophylactic and pro-regenerative activity in this liver damage model. BML-257 also showed remarkable protective action in two independent toxicological models of liver injury caused by acetaminophen and Isoniazid. This suggests that BML-257 may have the potential to protect against multiple kinds of drug induced liver injury.

2 October 2022 in arXiv
Verified
Preprint
Open access
PDF file
KCKuldeep Singh Charak
Kuldeep Singh Charak
NBNikhil Bharti
Nikhil Bharti
ASAnil Singh
Anil Singh
This article aims at finding sufficient conditions for a family of meromorphic functions to be normal by involving partial sharing of sets with differential polynomials. Moreover, corresponding results for normal meromorphic functions are also established which improve and generalize many known results.